All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Endothelial damage in target organs such as the colon, the liver and skin, as a consequence of steroid-refractory graft-versus-host disease (SR GvHD), has been suspected to increase mortality.1 The protection of intestinal organs from endothelial damage may provide a novel approach in order to improve the survival rates of patients with SR GvHD.
On 27 March 2019, at the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Dr. Olaf Penack, from Charité Univerisätsmedizin Berlin, Berlin, DE, discussed endothelial damage and protection of the endothelium in SR GvHD, including assessment of a non-immunosuppressive approach, utilizing the phosphodiesterase type 5 inhibitor, sildenafil.2
Murine models
Efficacy of in vitro sildenafil
Dr. Penack concluded that following allo-HSCT, the role of the endothelium in aGvHD is important to consider, with the results demonstrating that utilization of sildenafil as a non-immunosuppressive endothelial-protection treatment approach may improve outcomes in SR GvHD. These findings will need further validation, however, this supports the development of endothelial-targeted approaches for the treatment of SR GvHD.
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox